Insilico Medicine and Collaborators Identify Novel Alzheimer's Disease Targets Using AI
Insilico Medicine, in collaboration with researchers from the University of Oslo and Akershus University Hospital, has identified new therapeutic targets for Alzheimer's disease. This discovery was made possible through the integration of artificial intelligence (AI) and rigorous experimental validation. The research focused on the NAD+-mitophagy axis, a pathway crucial for healthy brain aging and neurodegeneration. By analyzing large-scale human data, the team demonstrated that molecular changes in these pathways are present in the early stages of Alzheimer's. The AI-driven target discovery platform, PandaOmics, evaluated over 100 candidate genes involved in NAD+ and mitophagy pathways, prioritizing five potential therapeutic targets: ULK1, OPA1, LAMP2, MFN1, and ATP6V0E1. Preclinical validation in various models, including C. elegans and human Tau-mutant cell lines, confirmed that modulating these target genes directly altered disease pathology. For instance, enhancing mitochondrial fusion via OPA1 activ...